Study of Acetyl-leucine for Improving Balance in Adults With Post-stroke Ataxia Following Ischemic Stroke

What this Trial Is About

Researchers are studying the safety and effectiveness of taking 4 grams of acetyl-leucine daily for three months in patients who have post-stroke ataxia following a posterior-circulation ischemic stroke. This clinical trial is designed as a double-blinded, placebo-controlled study to compare acetyl-leucine with a placebo in improving balance and movement issues after stroke. The study is conducted at Kafr-Elsheikh University and includes 200 patients who recently experienced this type of stroke. Participants are randomly assigned to one of two groups. One group receives 4 grams of acetyl-leucine daily along with aspirin and clopidogrel as part of their stroke treatment, while the other group receives a placebo with the same aspirin and clopidogrel regimen. The aspirin and clopidogrel are given as a loading dose during the first 24 hours after stroke, followed by a maintenance dose daily for 90 days. The interventions begin within 24 hours of stroke onset and continue for three months. During the study, participants will undergo brain imaging scans including CT and MRI to confirm stroke diagnosis and monitor progress. Researchers will assess balance and ataxia using the Berg Balance Scale BBS, Scale for the Assessment and Rating of Ataxia SARA, and Modified Rankin Scale mRS at 90 days. They will also monitor for any treatment-related side effects. The study lasts for three months, with detailed evaluations and safety assessments throughout this period.

Acetyl-leucine in Post-stroke Ataxia